Skip to content
The Mumbai

Senores Pharmaceuticals Sees Strong Q2 FY27 With 25% Revenue Jump, EBITDA Climbing 38% Amidst Portfolio Expansion

Senores Pharmaceuticals Sees Strong Q2 FY27 With 25% Revenue Jump, EBITDA Climbing 38% Amidst Portfolio Expansion
Photo: Free Press Journal · view original

Mumbai: Senores Pharmaceuticals Limited on Wednesday, 29 October 2026, reported its unaudited financial results for the quarter and half year ended 30 September 2026. The company's revenue for the second quarter of fiscal year 2027 grew by 25% year-on-year to ₹192 crore. Profitability Growth Earn...

Sources and story details